News | November 24, 2014

Fat Around the Heart May Cause AFib According to Loyola Study

Findings show that fat layers may be a better predictor than BMI

AFIB, BMI, Loyola University Medical Center, Epicardial Adipose Tissue

November 24, 2014 — Obesity is a known risk factor for atrial fibrillation (AFib), the most common heart rhythm disorder.

Obesity is commonly measured as a person’s body mass index (BMI), but a Loyola University Medical Center study has found that the layer of fat around the outside of the heart is more closely associated with atrial fibrillation than BMI.

“Many people who would not be considered obese by their BMI have high volumes of fat around their hearts, which could put them at risk for atrial fibrillation. Simple measures such as BMI may fail to completely inform us of a patient’s true cardiovascular risk,” says Mark Rabbat, M.D., first author of the study and an assistant professor of medicine and radiology, Division of Cardiology, at Loyola University Medical Center.

The study found a statistically significant correlation between the fat layer and scarring in the left atrium that causes atrial fibrillation. By contrast, there was not a statistically significant correlation between BMI and scarring in the left atrium of the heart.

AFib, occurs when the atria fibrillate. AFib is thought to be caused by inflammation and scarring (fibrosis) in the left atrium.

New innovations in cardiac magnetic resonance imaging enable physicians to precisely measure both epicardial adipose tissue (EAT) volume and the amount of fibrosis in the left atrium.

The study included 54 patients who had AFib. The average amount of fat around the heart (EAT volume) was 120 cubic centimeters. There was a statistically significant correlation of 0.45 between EAT volume and fibrosis. By comparison, there was only a 0.30 correlation between BMI and fibrosis – and this lower correlation was not statistically significant.

For many years, EAT was believed to be harmless, inert fat tissue, but it now appears that EAT is a metabolically active organ, releasing proteins that may trigger the fibrosis that causes AFib.

Weight loss, either through diet and exercise or through weight-loss surgery, has been shown to reduce the amount of EAT, but current medical treatments fail to specifically target EAT.

Rabbat remarks: “Fat tissue around the heart may be a novel target to reduce the risk of a-fib and its recurrence.”

The study is titled "Epicardial adipose tissue volume predicts extent of left atrial fibrosis in patients with atrial fibrillation."

Other co-authors of the study, all at Loyola, are Bassel Sayegh, M.D.; Andrew Stiff, M.D.; Brian Vetter, MS; Kim Chan, MBBS; Tonye Teme, M.D. and senior author David Wilber, M.D.

For more information: www.loyolamedicine.org

Related Content

A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development. #SCAI, #SCAI2018

A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development.  

Feature | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 – New clinical evidance shows common therapy options for psoriasis (PSO), a chronic inflammatory skin di
Intravenous Drug Use is Causing Rise in Heart Valve Infections, Healthcare Costs. #SCAI, #SCAI2018
News | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 — The opioid drug epidemic is impacting cardiology, with a new study finding the number of patients hosp
Patient Enrollment Completed in U.S. IDE Study of THERMOCOOL SMARTTOUCH SF Catheter
News | Cardiovascular Clinical Studies | March 15, 2018
March 15, 2018 –  Johnson & Johnson Medical Devices Companies announced today that Biosense Webster, Inc., who wo
Lexington Begins HeartSentry Clinical Trial
News | Cardiovascular Clinical Studies | February 20, 2018
February 20, 2018 – Lexington Biosciences, Inc., a development-stage medical device company, announced the commenceme
Endologix Completes Patient Enrollment in the ELEVATE IDE Clinical Study
News | Cardiovascular Clinical Studies | February 06, 2018
February 6, 2018 – Endologix, a developer and marketer of treatments for aortic disorders, announced the completion o
12-Month Results from Veryan Medical's MIMICS-2 IDE Study Presented at LINC
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 – Thomas Zeller (Bad Krozingen, Germany) presented the 12-month results from Veryan Medical’s MIMICS
LimFlow Completes U.S. Feasibility Study Enrollment, Receives FDA Device Status
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 –  LimFlow SA, developer of minimally-inv
ESC 2017 late breaking trial hot line study presentations.
News | Cardiovascular Clinical Studies | September 12, 2017
September 12, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking C
U.K., NHS studies, weekend effect, hospital admission, atrial fibrillation, heart failure
News | Cardiovascular Clinical Studies | June 28, 2016
New research shows patients admitted to National Health Service (NHS) hospitals in the United Kingdom for atrial...
stroke risk
News | Cardiovascular Clinical Studies | August 28, 2015
Most people assume strokes only happen to octogenarians, but recent evidence suggests that survivors of childhood can
Overlay Init